Program
The Program is subject to change up to the time of the conference.
Wednesday, May 7
Thursday, May 8
Friday, May 9
Download
Program as PDF-file (Version 1.0, February 2003; 3Mb)
Wednesday, May 7
|
17:00-18.30
19:30 |
 |
Meeting for members of the association
Get-Together at Heilig-Geist |
Thursday, May 8
|
08:15-08:30
|
|
Welcoming Address
Ch. Huber, Mainz |
|
||
| Session 1: "Fundamentals of Antigen-Specific Immunotherapy I" Chair: P. Coulie (Bruxelles), P. Walden (Berlin) |
||
|
||
|
08:30-09:00
|
|
"New strategies for the identification of tumor-associated gene products"
Ö. Türeci, Mainz |
|
||
|
09:00-09:30
|
|
"Naturally processed peptides derived from tumor associated antigens"
H.-G. Rammensee, Tübingen |
|
||
|
09:30-10:00
|
|
"NK receptors, susceptibility of tumor cells to NK recognition"
A. Moretta, Genova, Italy |
|
||
|
10:00-10:30
|
|
"T cell responses to leukemia-associated antigens after vaccination"
A. Pezzutto, Berlin |
|
||
|
10:30-11:00
|
|
Coffee Break, Poster Visits
|
|
||
| Session 2: "Fundamentals of Antigen-Specific Immunotherapy II " Chair: A. Moretta (Genova), H.-G. Rammensee (Tübingen) |
||
|
||
|
11:00-11:30
|
|
"Role of serine protease inhibitors (Serpins) in dendritic cell survival and tumor immune escape"
R. Offringa, Leiden, The Netherlands |
|
||
|
11:30-12:00
|
|
"Prediction and Reduction of Immunogenicity in Antibodies and Proteins with T cell Epitopes"
F. Carr, Aberdeen, U.K. |
|
||
|
12:00-12:30
|
|
"Fc receptor pathways in active and passive immunization in tumor immunotherapy"
J.V. Ravetch, New York, USA |
|
||
|
12:30-13:30
|
|
Lunch, Poster Visits
|
|
||
| Session 3: "Therapeutic Antibodies" Chair: B. Dörken (Berlin), G. Jung (Tübingen) |
||
|
||
|
13:30-14:00
|
|
"Epidermal growth factor receptor family as therapeutic target in cancer treatment"
U. Vanhoefer, Essen |
|
||
|
14:00-14:30
|
|
"Antibodies for hematologic malignancies: Current status and perspectives"
M. Gramatzki, Erlangen |
|
||
|
14:30-15:00
|
|
"Mechanism of action and preclinical activity of rhuMAb 2C4 (Pertuzumab)"
M. Hasmann, Penzberg |
|
||
|
15:00-15:30
|
|
"Recruitment of human effector cells by bispecific antibodies"
C. Renner, Homburg/Saar |
|
||
| Session 4: "Adoptive T Cell Transfer" Chair: R. Offringa (Leiden), Ch. Huber (Mainz) |
||
|
||
|
15:30-16:00
|
|
"Adoptive transfer of antigen-specific T cells"
P. Greenberg, Seattle, USA |
|
||
|
16:00-16:30
|
|
"Bypassing tolerance to malignant disease by T cell receptor transfer"
M. Theobald, Mainz |
|
||
|
16:30-17:00
|
|
Coffee Break, Poster Visits
|
|
||
| Session 5: "Short Presentations" 17:00-18:30 Chair: U. Trefzer (Berlin), Th. Wölfel (Mainz) |
||
|
||
|
17:00-17:15
|
|
"Patient specific analysis of tumor antigen expression and presentation followed by individual immunotherapy"
O. Schoor, Tübingen |
|
||
|
17:15-17:30
|
|
"Identification of human tumor antigens with cryopreserved non-clonal T cell populations"
V. Lennerz, Mainz |
|
||
|
17:30-17:45
|
|
"A chimeric CD19 antibody mediates effective lysis of acute leukemic blasts from pediatric patients transplanted with purified allogeneic CD34+ progenitors"
K. Barbin, Erlangen |
|
||
|
17:45-18:00
|
|
"A novel recombinant bispecific single-chain antibody, bscCD19xCD3, for the treatment of malignant B-cell lymphomas"
A. Löffler, Berlin |
|
||
|
18:00-18:15
|
|
"FcaRI-directed single chain bispecific antibodies for lymphoma therapy"
Y. Wachter, Erlangen-Nürnberg |
|
||
|
18:15-18:30
|
|
"Targeting CD19 with genetically modified Epstein-Barr-virus-specific human T lymphocytes"
C. Rössig, Münster |
|
||
|
19:30
|
|
Dinner at Moller's Restaurant (Staatstheater Mainz)
|
|
||
Friday, May 9
| Session 6: "Short Presentations" 08:30-9:30 Chair: S. Stevanovic (Tübingen), U. Sahin (Mainz) |
||
|
||
|
08:30-8:45
|
|
"Peptide Vaccination can induce high-frequency T cell responses and long-term freedom from relapsing skin metastases in melanoma"
A. Letsch, Berlin |
|
||
|
08:45-9:00
|
|
"WT1 vaccination induces specific T cell immunity and complete remission in a patient with relapsed AML"
V. Mailänder, Berlin |
|
||
|
09:00-9:15
|
|
"LUD00-009: Phase I study of intensive course immunization with NY-ESO peptides in HLA-A2+ patients with NY-ESO-1+ cancer"
E. Jäger, Frankfurt |
|
||
|
09:15-9.30
|
|
"mRNA as immunostimulatory molecule"
B. Scheel, Tübingen |
|
||
| Special Lecture Chair: S. Stevanovic (Tübingen), U. Sahin (Mainz) |
||
|
||
|
09.30-10:00
|
|
"Effector mechanisms of tumor rejection"
Th. Blankenstein, Berlin |
|
||
|
10:00-10:30
|
|
Coffee Break, Poster Visits
|
|
||
| Session 7: "Therapeutic Vaccination I" Chair: B. Seliger (Mainz), P. Brossart (Tübingen) |
||
|
||
|
10:30-11:00
|
|
"Transplantation-associated skin tumours: chances for preventive vaccination"
I. Nindl, Berlin |
|
||
|
11:00-11:30
|
|
"Immunological monitoring of anti-MAGE vaccination"
P. Coulie, Bruxelles, Belgium |
|
||
|
11:30-12:00
|
|
"Development of a recombinant idiotype vaccine for non-Hodgkin´s lymphoma"
H. Veelken, Freiburg |
|
||
|
12:00-13:00
|
|
Lunch, Poster Visits
|
|
||
| Session 8: "Therapeutic Vaccination II" Chair: P. Greenberg (Seattle), A. Pezzutto (Berlin) |
||
|
||
|
13:00-13:30
|
|
"Induction of anti-tumor immune responses using CpG DNA"
A.M. Krieg, Wellesley, USA |
|
||
|
13:30-14:00
|
|
"Use of dendritic cells in cancer immunotherapy"
G. Schuler, Erlangen |
|
||
|
14:00-14:30
|
|
"Cancer immunotherapy using tumor RNA-transfected dendritic cells"
E. Gilboa, Durham, USA |
|
||
|
14:30-15:00
|
|
"The EORTC program on therapeutic vaccination"
U. Keilholz, Berlin |
|
||
|
15.00-15:15
|
|
"CIMT - Call for Clinical Trials
"C. Britten, Mainz |
|
||
|
15:15-15:45
|
|
Coffee Break, Poster Visits
|
|
||
| Session 9: "Biotechnology and Regulatory Issues" Chair: E. Gilboa (Durham), G. Schuler (Erlangen) |
||
|
||
|
15:45-16:15
|
|
"Manufacturing of plasmid-DNA based drugs - process, quality, and product considerations"
M. Müller, Hilden |
|
||
|
16:15-16:45
|
|
"DNA/RNA-based vaccines: development, standardization and regulation"
K. Cichutek, Langen |
|
||
| Concluding Remarks | ||
|
||
|
16:45-17.00
|
|
H.-G. Rammensee / Ch. Huber
|
|
||
Download
Program as PDF-file (Version 1.0, February 2003; 3Mb)
